Loading...
Docoh

Aligos Therapeutics (ALGS)

News

From Benzinga Pro
Aligos Therapeutics Highlights Presentation Of 28-Day Safety, Efficacy And Pharmacokinetic Clinical Data For ALG-000184
22 Jun 22
Biotech, General
-Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic hepatitis B (CHB)
Aligos Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application
6 Jun 22
News
https://patentcenter.uspto.gov/#!/applications/16887063/ifw/docs
Aligos Therapeutics's Return On Capital Employed Insights
23 May 22
Earnings
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62 million.
Stocks That Hit 52-Week Lows On Thursday
5 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Thursday, 351 stocks hit new 52-week lows.
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
5 May 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Where Aligos Therapeutics Stands With Analysts
5 May 22
Analyst Ratings
Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings:
SVB Leerink Downgrades Aligos Therapeutics to Market Perform, Lowers Price Target to $3
5 May 22
News, Downgrades, Price Target, Analyst Ratings
SVB Leerink analyst Roanna Ruiz downgrades Aligos Therapeutics (NASDAQ:ALGS) from Outperform to Market Perform and lowers the price target from $7 to $3.
Aligos Therapeutics Q1 EPS $(0.84) Misses $(0.73) Estimate
4 May 22
Earnings, News
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.73) by 15.07 percent. This is a 13.51 percent decrease over losses of $(0.74) per share
Earnings Scheduled For May 4, 2022
4 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Preview: Aligos Therapeutics's Earnings
3 May 22
Earnings
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos Therapeutics will report an earnings per share (EPS) of $-0.73.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
26 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
18 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 466 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Friday
8 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Friday's morning session, 234 stocks hit new 52-week lows.